CP and chronic myelogenous leukemia, BCR-ABL1 positive: At 1 hour of PTL or DMAPT treatment CML cells from cell lines and CD34+lin− CML‐CP showed an increase in DCFDA MFI, compared to untreated cells, indicating an increase in ROS levels, importantly primitive cells from NBM did not show an increase in ROS levels.